In vitro Activity and Resistance Profile of Samatasvir , a Novel NS 5 A Replication Inhibitor 1 of Hepatitis C Virus 2

J. Bilello,L. Lallos,J. McCarville,M. Colla,I. Serra,C. Chapron,C. Pierra,N. D.,Standring,M. Seifer

Abstract:

What problem does this paper attempt to address?

In a "nutshell": intrinsically radio-labeled quantum dots.

W. Cai,H. Hong

Abstract:Quantum dots (QDs) have many intriguing properties suitable for biomedical imaging applications. The poor tissue penetration of optical imaging in general, including those using QDs, has motivated the development of various QD-based dual-modality imaging agents. In this issue of AJNMMI (http://www.ajnmmi.us), Sun et al. reported the synthesis and in vitro/in vivo characterization of intrinsically radio-labeled QDs (r-QDs), where (109)Cd was incorporated into the core/shell of QDs of various compositions. These r-QDs emit in the near-infrared range, have long circulation half-life, are quite stable with low cytotoxicity, exhibit small size and low accumulation in the reticuloendothelial system, and can allow for accurate measurement of their biodistribution in mice. With these desirable features demonstrated in this study, future development and optimization will further enhance the biomedical potential of intrinsically radio-labeled QDs.
Effective management of recurrent Doege-Potter syndrome with somatostatin-analogues: A case report

Felix Schöler,Maximilian Andreas Storz,Ashkan Khavaran,Nicolas Hümmler,Maximilian Frederik Russe,Christoph-Ferdinand Wielenberg,Katharina Laubner,Jochen Seufert

DOI: https://doi.org/10.1002/cnr2.1992

Abstract:Background: Doege-Potter syndrome is defined as paraneoplastic hypoinsulinemic hypoglycemia associated with a benign or malignant solitary fibrous tumor frequently located in pleural, but also extrapleural sites. Hypoglycemia can be attributed to paraneoplastic secretion of "Big-IGF-II," a precursor of Insulin-like growth factor-II. This prohormone aberrantly binds to and activates insulin receptors, with consecutive initiation of common insulin actions such as inhibition of gluconeogenesis, activation of glycolysis and stimulation of cellular glucose uptake culminating in recurrent tumor-induced hypoglycemic episodes. Complete tumor resection or debulking surgery is considered the most promising treatment for DPS. Case: Here, we report a rare case of a recurrent Doege-Poter Syndrome with atypical gelatinous tumor lesions of the lung, pleura and pericardial fat tissue in an 87-year-old woman. Although previously described as ineffective, we propose that adjuvant treatment with Octreotide in conjunction with intravenous glucose helped to maintain tolerable blood glucose levels before tumor resection. The somatostatin-analogue Lanreotide was successfully used after tumor debulking surgery (R2-resection) to maintain adequate blood glucose control. Conclusion: We conclude that somatostatin-analogues bear the potential of being effective in conjunction with limited surgical approaches for the treatment of hypoglycemia in recurrent or non-totally resectable SFT entities underlying DPS.
Non-Islet-Cell Tumor Hypoglycemia Secondary to Malignant Phyllodes Tumor of the Breast

Si Min Lee,Timothy Peng Lim Quek,Cherng Jye Seow,Pei Shan Yeo

DOI: https://doi.org/10.1016/j.aace.2024.07.002

2024-07-15

Abstract:Background/objective: Non-islet cell tumor hypoglycemia (NICTH) is an uncommon condition, of which only a few cases caused by malignant phyllodes tumor of the breast have been reported. We describe a case of NICTH secondary to malignant phyllodes tumor with good response to glucocorticoid therapy. Case report: A 62-year-old woman with a rapidly enlarging left breast mass presented with drowsiness and a capillary blood glucose level of 32.4 mg/dL. Her plasma glucose and insulin levels were 36.0 mg/dL (reference range, 72-144 mg/dL) and 0.6 mIU/L (reference range, 0.0-25.0 mIU/L), respectively. Her beta-hydroxybutyrate and c-peptide levels were undetectable. The insulin-like growth factor (IGF)-I and IGF-II levels were 37 μg/L (reference range, 43-220 μg/L) and 1062 ng/mL (reference range, 333-967 ng/mL), respectively, with an IGF-II:IGF-I molar ratio of 29.4. Prednisolone 30 mg per day was initiated with improvement in hypoglycemia. Outpatient flash glucose monitoring profile was stable with mild hypoglycemia (glucose level, 54-68.5 mg/dL) detected 5% of the time. The patient underwent left mastectomy with axillary clearance 4 weeks later. Histology was reported as malignant phyllodes tumor with extensive ductal carcinoma in situ. Prednisolone was stopped after surgery. The patient was treated with letrozole and adjuvant radiotherapy. There was no recurrence of hypoglycemia during the subsequent 24-month follow-up. Discussion: The mainstay of treatment for NICTH is surgical resection of the culprit tumor. Although glucocorticoid treatment has also been widely used for NICTH, few reports have demonstrated efficacy for NICTH secondary to phyllodes tumor. Conclusion: We report a rare case of malignant phyllodes tumor of the breast resulting in NICTH and demonstrated good response to glucocorticoids as a bridge to definitive surgery.
Clinical characteristics of gastrointestinal stromal tumors with hypoglycemia

Akihiko Chida,Kenta Kawasaki,Junko Kuramoto,Hideyuki Hayashi,Toru Kawahara,Satomi Makiuchi,Eiichiro So,Satoko Shimizu,Shotaro Kishimoto,Sara Horie,Yuki Saito,Keitaro Shimozaki,Kai Tsugaru,Kazuhiro Togasaki,Kenro Hirata,Hiroshi Nishihara,Yae Kanai,Takanori Kanai,Yasuo Hamamoto

DOI: https://doi.org/10.3892/ol.2024.14701

2024-09-28

Oncology Letters

Abstract:The development of tyrosine‐kinase inhibitors has improved survival rates for patients with gastrointestinal stromal tumors (GISTs). Despite the progress, not all the patients can universally receive the benefit from treatment due to the individual underlying conditions in a real‐world setting. The present study focused on the well‐known but understudied condition of GIST with hypoglycemia. Hypoglycemia in GIST is characterized by hypoglycemic symptoms such as dizziness, sweating and confusion. It is caused by several factors such as multiple liver metastases, drug adverse effects, postoperative complications and paraneoplastic syndrome [non‐islet cell tumor hypoglycemia (NICTH)]. Comprehensive analysis of this condition has been hindered due to its rarity, and has been mostly limited to case reports. In the present study, a single‐institution retrospective analysis of GIST with hypoglycemia was conducted to investigate its prevalence and prognosis, and the cause of this condition. The present study identified that the prevalence of hypoglycemic episodes of GIST was 4.1% in all patients with GIST, and recurrent hypoglycemic cases had a poor prognosis. The present study identified 1 case with recurrent hypoglycemia due to NICTH. Since NICTH is a rare hypoglycemic cause and requires further evaluation, an autopsy and genetic sequencing were performed using the available clinical materials. Through this histological and genetic investigation, the histological diversity of NICTH‐GIST was revealed and insulin‐like growth factor II (IGF‐II) amplification was identified. Furthermore, a chronological analysis was performed using multiple resected archived samples from the same case, and revealed that diffuse IGF‐II expression may have occurred in the early phase of tumor development. The present study catalogued the characteristics of GIST with hypoglycemia with a focus on NICTH‐GIST.

oncology
Targeting-intratumoral-lactic-acidosis Transcatheter-Arterial-chemoembolization for Non-Islet Cell Tumor Hypoglycemia Secondary to a Liver Metastatic Solitary Fibrous Tumor: A Case Report and Literature Review.

Kai Jin,Shan Zhong,Liya Lin,Jianjun Wu,Yuqi Wang,Weijuan Cui,Wei Gu,Ming Chao,Xiaoxiao Song

DOI: https://doi.org/10.3389/fendo.2022.955687

IF: 6.055

2022-01-01

Frontiers in Endocrinology

Abstract:Doege-Potter syndrome is a rare paraneoplastic syndrome characterized by non-islet cell tumor hypoglycemia secondary to a solitary fibrous tumor. Doege-Potter syndrome always presents with recurrent fasting hypoglycemia, which can occasionally be life-threatening. The best choice of treatment for Doege-Potter syndrome and solitary fibrous tumor is complete resection. However, when it is unfeasible, local-regional treatment can be used as a palliative therapy. Herein, we report a case of a 46-year-old man with Doege-Potter syndrome that occurred secondary to the liver and pancreatic metastatic solitary fibrous tumors. After he received six rounds of targeting-intratumoral-lactic-acidosis transcatheter-arterial-chemoembolization (TILA-TACE) treatment in our hospital, his hypoglycemia was clinically cured, and the liver metastatic tumor was well controlled. We suggest that TILA-TACE can be considered when curative resection is unfeasible for metastatic liver solitary fibrous tumors to help a patient obtain further surgery opportunities.
Paraneoplastic hypoglycemia: An overview for optimal clinical guidance

Nikolaos Nektarios Karamanolis,Dimitris Kounatidis,Natalia G Vallianou,Konstantinos Alexandropoulos,Eleni Kovlakidi,Pinelopi Kaparou,Irene Karampela,Theodora Stratigou,Maria Dalamaga

DOI: https://doi.org/10.1016/j.metop.2024.100305

2024-07-30

Abstract:Paraneoplastic hypoglycemia, also known as non-islet cell tumor hypoglycemia (NICTH), is a rare but critical condition occurring in patients with different types of malignancy. This condition is commonly linked to tumors producing insulin-like growth (IGF) factors, particularly IGF-2 and its precursors, which disrupt glucose homeostasis and lead to excessive glucose consumption. The diagnosis typically involves documenting symptomatic hypoglycemia and ruling out other potential causes. Essential diagnostic tools include imaging studies and laboratory tests, specifically measuring IGF-2 levels and the IGF-2:IGF-1 ratio. Treatment strategies for NICTH are multifaceted and may include surgical resection of the tumor if feasible, pharmacological interventions such as corticosteroids to suppress IGF-2 production, or supportive measures to manage acute hypoglycemic episodes. Novel therapeutic approaches targeting IGF-2, such as monoclonal antibodies or siRNA, are also being explored and hold promise for future treatment options. This review aims to enhance understanding of paraneoplastic hypoglycemia, focusing on its pathogenesis and diagnosis, to guide optimal medical treatment.
A Case of Nonislet Cell Tumor Hypoglycemia Due to Metastatic Salivary Myoepithelial Carcinoma

Margaret C Slack,Samantha Sovich,Chana R Sachs,Dorothy Martinez,Run Yu

DOI: https://doi.org/10.1016/j.aace.2024.06.002

2024-06-18

Abstract:Background/objective: Nonislet cell tumor hypoglycemia (NICTH) is an uncommon cause of hypoglycemia due to a relative surplus of insulin-like growth factor 2 (IGF-2) or its precursor molecule. The diagnosis is confirmed by an elevated ratio of IGF-2 to insulin-like growth factor 1 (IGF-1). Myoepithelial carcinoma (MECA) is a rare and aggressive salivary gland cancer that has not been previously associated with NICTH. Case report: A 63-year-old female with a past medical history of metastatic salivary MECA, type 2 diabetes mellitus previously on metformin, hypertension, and hypothyroidism presented to her oncologist for chemotherapy and was found to have a serum glucose of 30 mg/dL (reference: 65-99). She was admitted for further diagnostic work-up which revealed an insulin level of <1 μU/mL (reference: 3-25), C-peptide <0.5 ng/mL (reference: 1.1-4.3), IGF-1 of 15 ng/mL (reference: 41-279), and IGF-2 of 147 ng/mL (reference: 180-580) with an IGF-2:IGF-1 molar ratio of 10, consistent with NICTH. The patient's hypoglycemia unfortunately was quite resistant to treatment, requiring a combination of corticosteroids, continuous dextrose infusion, and somatostatin injections. The patient died 3 weeks after presenting with hypoglycemia. Discussion: Salivary MRCAs commonly contain pleomorphic adenoma gene 1 oncogene rearrangements which are associated with increased IGF-2 production and may predispose patients to hypoglycemia. Conclusion: This case demonstrates that NICTH can be associated with metastatic salivary MECA. The hypoglycemia in this scenario is challenging to manage and is associated with poor prognosis.
Initial Presentation of Ovarian Carcinosarcoma With Non-islet Cell Tumor Hypoglycemia: A Case Report

Shatha Elemian,Samer Jumean,Amy Paige,Shahd Yaghi,Hamid S Shaaban

DOI: https://doi.org/10.7759/cureus.65825

2024-07-31

Cureus

Abstract:Ovarian cancer, although not among the most commonly diagnosed cancers, remains a significant cause of cancer-related mortality in females. Several paraneoplastic syndromes have been associated, and this case study represents a rare manifestation of ovarian cancer, presenting as non-islet cell tumor hypoglycemia (NICTH), characterized by the excessive production of insulin-like growth factor-II (IGF-II) by tumor cells. We report a 55-year-old woman who presented to our hospital with abdominal distension and severe refractory hypoglycemia. The laboratory data revealed the suppression of serum insulin and C-peptide levels. The insulin-like growth factor II (IGF-II)/insulin-like growth factor 1 (IGF1) ratio was >32. The hypoglycemia was hence attributed to the non-islet cell tumor type, and it is likely driven by tumoral secretion of incompletely processed IGF-II. The lab findings suggested the existence of NICTH. Abdominal computed tomography demonstrated the presence of a left ovarian mass and peritoneal carcinomatosis. CT-guided biopsy of the peritoneal lesions showed poorly differentiated malignancy consistent with ovarian carcinosarcoma (OCS). The patient was treated with a continuous infusion of glucose. She even received oral prednisone and glucagon infusion. Chemotherapy with carboplatin and paclitaxel was initiated, but unfortunately, she died from complications of multiorgan failure. To our knowledge, this is the first novel case of an initial presentation of metastatic OCS with NICTH, underscoring the complexity of ovarian cancer presentations and the necessity of a comprehensive approach in managing rare paraneoplastic syndromes, such as NICTH.
Non-islet cell tumor-induced hypoglycemia due to overproduction of insulin-like growth factor-II--two case reports and literature review

陆洁莉,赵咏桔,唐金凤,刘建民,王卫庆,张炜,顾燕云,罗邦尧,李小英,宁光

2004-01-01

Abstract:2例非胰岛细胞肿瘤性低血糖(NICTH)患者血清中胰岛素样生长因子(IGF)-Ⅱ水平增高,IGF-Ⅰ、IGF结合蛋白(BP)-3、GH水平受到抑制,IGF-Ⅱ/IGF-Ⅰ异常增高,其中1例间质来源的肿瘤患者术后循环GH-IGF轴恢复至正常范围,表明循环GH-IGF轴改变在NICTH的定性诊断中具有重要价值,IGF-Ⅱ/IGF-Ⅰ是敏感性较高的参数。
A Giant Borderline Phyllodes Tumor of Breast With Skin Ulceration Leading to Non-Insular Tumorigenic Hypoglycemia: A Case Report and Literature Review

Jinlu Zhao,Meizhuo Gao,Yi Ren,Shaodong Cao,He Wang,Ruisheng Ge

DOI: https://doi.org/10.3389/fendo.2021.651568

2021-03-25

Abstract:Phyllodes tumor (PT) is a special type of breast tumors, including three types: malignant, borderline, and benign. Most of these tumors form unilateral disease and can rapidly increase in size. The occurrence of axillary lymph node metastasis is rare. Tumor-associated hypoglycemia can be divided into non-islet cell tumor and insulinoma. In non-islet cell tumor hypoglycemia (NICTH), a considerable high molecular weight form of insulin like growth factor 2 (IGF-2) is formed, which abnormally binds to insulin receptors in the tissues and causes hypoglycemia. Breast phyllodes tumors with NICTH are rare and first reported in 1983. Surgical resection is the main treatment and hypoglycemia symptoms usually resolve after surgery. Nevertheless, prior to surgery, intravenous glucose infusion is used to maintain blood glucose levels. A female patient presented with a rapidly growing breast mass and was diagnosed with a phyllodes tumor with NICTH at our hospital in August 2020; she was successfully treated through surgical resection. We reviewed the relevant literature to investigate and analyze the relationship between NICTH and phyllodes tumors, as well as optimize its diagnosis and treatment.
Malignant solitary fibrous tumor of the kidney with IGF2 secretion and without hypoglycemia

Luting Zhou,Yang Liu,Teng Xu,Lei Dong,Xiaoqun Yang,Chaofu Wang

DOI: https://doi.org/10.1186/s12957-024-03342-4

2024-07-09

Abstract:Background: Solitary fibrous tumor (SFT) is a rare fibroblastic mesenchymal tumor that mostly involves the pleura and infrequently involves extra-pleural sites. De novo SFT of the kidney is uncommon, and malignant SFT is extremely rare. Case presentation: We report a case of a 51-year-old man with a large malignant SFT in the left kidney. Pathological examination confirmed the diagnosis of SFT based on typical morphology, nuclear STAT6 expression, and NAB2-STAT6 gene fusion. The malignant subtype was determined by a large tumor size (≥ 15 cm) and high mitotic counts (8/10 high-power fields). KRAS mutation was identified by DNA sequencing. Insulin-like growth factor 2 (IGF2) was diffusely and strongly expressed in tumor cells, however, hypoglycemia was not observed. Hyperglycemia and high adrenocorticotropic hormone (ACTH) concentration were observed one month after surgery. Hormone measurements revealed normal blood cortisol and aldosterone levels, and increased urinary free cortisol level. A pituitary microadenoma was identified using brain magnetic resonance imaging, which may be responsible for the promotion of hyperglycemia. Conclusions: We report a case of renal malignant SFT with a KRAS mutation, which was previously unreported in SFT and may be associated with its malignant behavior. Additionally, we emphasize that malignant SFT commonly causes severe hypoglycemia due to the production of IGF2. However, this effect may be masked by the presence of other lesions that promote hyperglycemia. Therefore, when encountering a malignant SFT with diffuse and strong IGF2 expression and without hypoglycemia, other lesions promoting hyperglycemia need to be ruled out.
A Novel Medical Treatment of Cushing's Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1

Gul Bano,Farheen Mir,Nigel Beharry,Philip Wilson,Shirley Hodgson,Stephen Schey

DOI: https://doi.org/10.5812/ijem.6898

2012-12-21

International Journal of Endocrinology and Metabolism

Abstract:A 64-year-old male presented with neurofibromatosis 1 and Cushing's syndrome. Clinically he was over weight, depressed with extensive skin bruising and hypertension. His 24 hours urinary metanephrines, urinary 5HIAA, gut peptides and chromgranin levels were normal. His renal function and renal MRI scan was also normal. His cortisol failed to suppress on overnight dexamethsone suppression test. His low dose dexamethasone suppression with CRH stimulation showed failure of suppression of cortisol to < 50 nmol/L and ACTH was measurable at 10 ng/L on day 3. There was no response of ACTH or cortisol to CRH stimulation. His ACTH precursors were high at 126 pmol/L consistent with defective pro-opiomelanocortin (POMC) processing suggesting an ectopic source of ACTH production. The MRI scan of his pituitary and CT scan of the adrenal glands was normal. His octreotide scan was negative. The source of his ectopic ACTH was most likely a large retroperitoneal plexiform neurofibroma seen on CT abdomen that had undergone malignant peripheral nerve sheath tumour transformation on histology. He was a poor surgical risk for tumour debulking procedure. In view of the available literature and role of c-kit signalling in neurofibromatosis, he was treated with Imitinib. Four months after the treatment his Cushings had resolved on biochemical testing. After a year his plexiform neurofibroma has not increased in size. To our knowledge, this is the first case of NF1 associated with clinical and biochemical features of Cushing's secondary to ectopic ACTH due to MPNST in a plexiform neurofibroma and its resolution on treatment with imatinib.
P-43 Pancreatic insulinoma with delayed challenging diagnosis by 68Ga-DOTATATE PET/CT scan: Case report

Khdair Hazbar Razzaq,Dheyaa Al-Waeli,Mohanad Abdulretha,Hameed Naeem Mosa

DOI: https://doi.org/10.1210/jcemcr/luad146.044

2024-01-01

Abstract:Abstract Introduction Insulinoma (I) is most common neuroendocrine pancreatic tumor with an incidence of 0.1-0.3/100000(1). It is faintly more in females and can develop at any age(2). Usually benign, sporadic, less than 2 cm, solitary and in 10% of cases is multiple and happens as a component of multiple endocrine neoplasia syndrome type I (MEN–I)(3). Nonspecific symptoms may lead to delayed or misdiagnosis. Improper insulin secretion causes clinical features of hypoglycemia(2). Laboratory verification, localization followed by surgical removal are the main steps management. Localization may be difficult and delayed as here. Clinical Case A female of 58 years old with episodes of sweating, palpitation and tremor improved by drinking sweets, weight gain and denied any drugs intake. No personal or family history of diabetes or antidiabetic drugs. Body weight was 87 kg. Investigations during the attack showed low plasma glucose of 36 mg/dL, high serum insulin of 94.8 mIU/L (1.7 - 31), elevated C-peptide of 10.6 ng/mL (0.9-4). Cortisol and thyroid function are normal. Abdominal ultrasound (US), CT scan and MRI are normal. Due to failure of localization of Insulinoma, treatment by diazoxide started with no response. Octreotide long-acting repeatable (Octreotide LAR) 20 mg monthly injection was initiated and increased to 30 mg monthly with good improvement and less attacks. After three years, the patient developed abdominal pain and abdominal US showed multiple gall stones. The patient was advised to do 68Ga-DOTATATE PET/CT Scan, which revealed distal pancreatic mass of 26 mm (Figure1A and B). Distal pancreatectomy and cholecystectomy had been done with smooth postoperative period normal normal plasma glucose, insulin and c-peptide with no further hypoglycemia, histopathological examination confirmed Insulinoma (Figure 2A and B). Hypoglycemic symptoms of I, whether neuroglycopenic or sympathoadrenal are precipitated by fasting or exercise and could precede diagnosis by months and even years(3). Insulinoma, should be suggested when patient has typical Whipple's triad, high insulin, c-peptide and proinsulin during the attack(3). Weight gain noted in about 18% of cases(4). Modalities used to localize Insulinoma include trans-abdominal US, CT scan, MRI, EUS (endoscopic ultrasound), intraoperative US, intraoperative palpation and arteriography. An American study considered 68Ga-DOTATATE PET/CT as an adjuvant tool for diagnosis with 90% detection rate (5). A 90-95% of cases are benign, patients have high survival with complete resolution of symptoms after excision with only 5.4% recurrences(6). Malignant I limited to pancreas and responsive to chemotherapy has 5 years survival rate after resection and 19 months for recurrent tumors(6). Conclusion Insulinoma should be considered in patients with typical clinical and laboratory finding. Follow up, assessment and different imaging techniques are main steps in management with teamwork.Figure 1.68Ga-DOTATATE PET/CT Scan68Ga-DOTATATE PET/CT Scan revealed distal pancreatic mass of 26 mm
Characteristics and treatment of a silent somatotroph tumor that had transformed to a functional type: a case report and literature review

Zhenwei Li,Yinzi Wu,Jian Sun,Renzhi Wang,Xinjie Bao

DOI: https://doi.org/10.21037/gs-24-79

2024-07-30

Abstract:Background: "Functionalization" of silent pituitary neuroendocrine tumors (PitNETs) is a pretty rare clinical phenomenon that reportedly occurs most often with silent corticotroph tumors (SCTs). We report the case of silent somatotroph tumor (SST) that had transformed to functional type. We also review similar cases of SST with functionalization. Case description: A 43-year-old man without suggestive symptoms of a pituitary tumor was referred with a lesion in the sellar region detected incidentally. Serum insulin-like growth factor 1 (IGF-1) (348 ng/mL) was high, whereas growth hormone (GH) was within the normal range. A glucose GH inhibition test showed inhibition of GH to 0.4 ng/mL. Subtotal tumorectomy was performed via a transnasal-sphenoidal approach. Histopathological examination of the operative specimen showed weak expression of GH and diffuse staining of pituitary-specific transcription factor-1 (Pit-1). The final pathological diagnosis was SST. Five years after the first surgery without follow-up, the patient presented again because of headache, impaired vision, bone pain, and high blood glucose concentrations for 2 months. Physical examination showed early acromegalic features. Of interest, greatly increased concentrations of GH (7.2 ng/mL) and IGF-1 (533 ng/mL) were found. Magnetic resonance imaging showed the recurrence of tumor. A diagnosis of acromegaly was considered. The patient underwent a second transsphenoidal pituitary tumor resection, after which his serum GH and IGF-1 concentrations decreased. Unlike the original surgical specimen, immunohistochemical examination of the tissue resected during the second surgery showed strong GH positivity, with similarly strong Pit-1 positivity. The patient was followed up for 6 months without octreotide treatment. At the last follow-up, he was found to have high serum concentrations of GH and IGF-1, which demonstrated another progression of the remnant PitNET. After two courses of octreotide acetate microspheres (20 mg/month), the acromegaly was under control. Conclusions: In addition to SCTs, other silent PitNETs could also functionalize. Medical teams of PitNETs should recognize this rare phenomenon and conduct long-term follow-up. After functionalization, these tumors have a high recurrence rate, requiring multiple therapies and long-term follow-up. Further research is essential to determine the mechanism of regulation of secretion of GH by such tumors.
THE VALUE OF ROUTINE PROCTOSCOPY FOR SURGEONS.

E. Fishel,R. T. Shackelford

The American Surgeon

Abstract:
Total management of hemangiopericytoma/solitary fibrous tumor of the buttock: A case report

Kazuhiko Hashimoto,Shunji Nishimura,Tomohiko Ito,Ryosuke Kakinoki,Koji Goto

DOI: https://doi.org/10.1097/MD.0000000000039044

2024-07-19

Abstract:Background: Solitary fibrous tumors can manifest at various anatomical sites, predominantly occurring at extrapleural sites with a peak incidence between 40 and 70 years. SFT necessitates long-term follow-up owing to its tumor characteristics. However, comprehensive reports covering the period from initial diagnosis to the patient's demise are lacking. Herein, we present a case of a malignant SFT of the buttocks that was treated at our hospital from the time of initial diagnosis to the end of life, with a literature review. Methods: A 54-year-old woman had a T1 low-to-isobaric and T2 isobaric-to-hyperintense mass in the psoas muscle on magnetic resonance imaging, diagnosed as an SFT. Wide excision was performed, followed by postoperative radiotherapy and chemotherapy. Multiple lung metastases were treated, while bone metastases appeared in the left femur. Multiple spinal metastases developed, causing respiratory distress due to pleural effusion. Best support care was initiated; however, a thrombus appeared in the inferior vena cava. Despite anticoagulant therapy, the patient died 11 years and 6 months after the initial surgery. Herein, marginal resection resulted in a relatively short operative time and average blood loss. The radiotherapy dose was 66 Gy; no complications occurred, and local recurrence was prevented. Tumor arthroplasty was performed to stabilize the affected limbs, and the patient required careful follow-up. Results: Despite the poor prognosis, the patient survived >11 years after surgery and had a favorable outcome. Conclusion: Long-term monitoring for potential complications remains necessary.
[Diagnosis and Surgical Treatment for Non-Functional Islet Cell Tumor: a Retrospective Analysis of 44 Cases].

Kui-rong Jiang,Yi Miao,Ze-kuan Xu,Zhu-yin Qian,Cun-cai Dai,Li Xie,Jun-li Wu,Qiang Li,Chun-hua Xi,Feng Guo,Jian-min Chen,Wen-tao Gao,Xun-Liang Liu

DOI: https://doi.org/10.3760/cma.j.issn.0529-5815.2009.05.003

2009-01-01

Abstract:OBJECTIVE:To evaluate the methods of diagnosis and surgical treatment for nonfunctional islet cell tumor (NICT).METHODS:Forty-four patients with non-functional islet cell tumor treated at the First Affiliated Hospital of Nanjing Medical University during January 1968 to June 2008 were analyzed retrospectively. There were 9 males and 35 females, aged from 7- to 70-years-old. Clinical manifestation: 15 cases (34.1%) of abdominal masses, 17 patients (38.6%) with epigastric or back pain, 5 cases of jaundice, 5 cases (11.4%) for upper abdominal fullness or vomiting, 10 cases (22.7%) of pancreatic tumor noticed by routine health checkups or imaging examinations. Imaging examination: CT scan, sonography, ERCP, MRI, upper GI series were performed in 33 (75.0%), 16 (36.4%), 6 (13.6%), 2 (4.5%), and 10 cases (22.7%) respectively. Operation methods: 39 patients (88.6%) underwent surgical resection and the other 5 patients did not.RESULTS:COMPLICATIONS:pancreatic fistula in 7 patients (15.9%), intra-abdominal bleeding in 4 (9.1%), gastrojejunal anastomosis outlet obstruction in 1 (2.3%), biliary fistula in 2 (4.5%) and incisional infection in 3 (6.8%). Surgery related mortality happened in 2 patients (4.5%), both treated before 1999. Twenty-five patients underwent operation between January 1999 and June 2008 were followed up for 6 to 108 months. All survive except one died 75 months after the surgery for unknown reason.CONCLUSIONS:No specific clinical manifestation is recognized for non-functional islet cell tumor. Spiral CT is an optimal diagnostic method, while surgery is the first choice for treatment. Middle segmental pancreatectomy has become an alternative surgical protocol for NICT.
Doege-Potter syndrome due to a solitary fibrous tumor of the pleura: a case report

Juan Estrada-Maya,Juan Sebastián Montejo,Katerin Dayana Báez López,Juan Carlos Garzón

DOI: https://doi.org/10.1186/s13256-024-04658-1

2024-08-14

Abstract:Background: Doege-Potter syndrome is a rare paraneoplastic phenomenon associated with solitary fibrous tumors of the pleura (SFTPs). It is characterized by the presence of severe, sustained, and treatment-refractory hypoglycemia. Hypoglycaemia, which may be the sole symptom at disease onset, is mediated by the secretion of high-molecular-weight insulin-like growth factor (IGF-2). Most tumors exhibit benign behavior, with a 100% survival rate at 5 years. However, 10% of these tumors may display aggressive behavior with local or metastatic recurrence. We present a clinical case of a patient with a benign solitary fibrous tumor of the pleura who presented with symptomatic hypoglycemia and required pulmonary and pleural surgical resection to control the paraneoplastic phenomenon. Case presentation: A Hispanic 46-year-old man presented with a 15-day history of transient alterations in consciousness worsened by fasting. The relevant medical history included obstructive sleep apnea treated with continuous positive air pressure (CPAP) and previous smoking. In-hospital studies revealed noninsulinemic hypoglycemia and a benign SFTP. Complete surgical resection was performed while the patient received dextrose fluids and corticosteroids perioperatively for hypoglycemia. Subsequently, the hypoglycemia resolved, and the patient was followed-up without disease recurrence. Conclusion: Doege-Potter syndrome is challenging to recognize. However, effective treatment can be achieved with a high survival rate. Raising awareness among healthcare professionals about the recognition of this paraneoplasic syndrome patients will improve diagnostic suspicion, biochemical confirmation, the development of diagnostic and therapeutic guidelines, and the creation of predictive indices for aggressive presentations requiring closer monitoring.
Heterogeneity of Multiple Pancreatic Neuroendocrine Tumors Identified by 68Ga-DOTANOC and 68Ga-exendin-4 PET/CT in a Patient with Endogenous Hyperinsulinemic Hypoglycemia and Multiple Endocrine Neoplasia 1

Junyan Xu,Xiaoping Xu,Meng Zhang,Wensheng Liu,Jie Chen,Shaoli Song

DOI: https://doi.org/10.1159/000538285

2024-03-12

Neuroendocrinology

Abstract:Insulinomas are the most frequent functional neuroendocrine tumors of pancreas. In about 10% cases, insulinomas are associated with hereditary syndrome including multiple endocrine neoplasia 1 (MEN1). Herein, we presented a case of 44-year-old female with recurrent hypoglycemia. In December 1998, this patient has undergone resection of two pancreatic lesions due to hypoglycemia and diagnosed as insulinoma. After operation, the symptom of hypoglycemia disappeared. However, from 2021, hypoglycemic symptoms reappeared frequently and even coma. In June 2023, enhanced CT showed multiple pancreatic lesions abundant with blood supply. Fasting serum blood glucose and insulin were 1.73mmol/L and 15.2U/L (2.6-11.8U/L). Germline genes suggested MEN1 pathogenic mutations. 68Ga-DOTANOC PET/CT indicated there were multiple lesions located in the pancreas and duodenum with high expression of somatostatin receptor (SSTR). 68Ga-exendin-4 PET/CT were added to localize the insulinoma. Most lesions with high expression of SSTR in body and tail of pancreas manifested part of them with high uptake of 68Ga-exendin-4, and an additional lesion with high expression of glucagon-like peptide 1 receptor was only detected by 68Ga-exendin-4 PET/CT. It showed highly heterogeneity. From the distal pancreatectomy, a total 5 tumors were found in the body and tail of pancreas, which were diagnosed as neuroendocrine tumors (NETs). After the operation, all the symptoms related to hypoglycemia disappeared. Immunohistochemical results of SSTR2 and insulin were consistent with the imaging finding of dual tracer PET/CT. From this case, combination of 68Ga-DOTANOC and 68Ga-exendin-4 PET/CT was recommended in the patients of MEN1 and insulinoma to estimate the heterogeneity of multiple neuroendocrine tumors that contributing to detect all the NET lesions and locate the tumors with secretion of insulin.

neurosciences,endocrinology & metabolism
Electroconvulsive Therapy Resurrected: Its Successes and Promises after 75 Years

M. Fink

DOI: https://doi.org/10.1177/070674371105600102

2011-01-01

Abstract:

In vitro Activity and Resistance Profile of Samatasvir , a Novel NS 5 A Replication Inhibitor 1 of Hepatitis C Virus 2

In a "nutshell": intrinsically radio-labeled quantum dots.

Effective management of recurrent Doege-Potter syndrome with somatostatin-analogues: A case report

Non-Islet-Cell Tumor Hypoglycemia Secondary to Malignant Phyllodes Tumor of the Breast

Clinical characteristics of gastrointestinal stromal tumors with hypoglycemia

Targeting-intratumoral-lactic-acidosis Transcatheter-Arterial-chemoembolization for Non-Islet Cell Tumor Hypoglycemia Secondary to a Liver Metastatic Solitary Fibrous Tumor: A Case Report and Literature Review.

Paraneoplastic hypoglycemia: An overview for optimal clinical guidance

A Case of Nonislet Cell Tumor Hypoglycemia Due to Metastatic Salivary Myoepithelial Carcinoma

Initial Presentation of Ovarian Carcinosarcoma With Non-islet Cell Tumor Hypoglycemia: A Case Report

Non-islet cell tumor-induced hypoglycemia due to overproduction of insulin-like growth factor-II--two case reports and literature review

A Giant Borderline Phyllodes Tumor of Breast With Skin Ulceration Leading to Non-Insular Tumorigenic Hypoglycemia: A Case Report and Literature Review

Malignant solitary fibrous tumor of the kidney with IGF2 secretion and without hypoglycemia

A Novel Medical Treatment of Cushing's Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1

P-43 Pancreatic insulinoma with delayed challenging diagnosis by 68Ga-DOTATATE PET/CT scan: Case report

Characteristics and treatment of a silent somatotroph tumor that had transformed to a functional type: a case report and literature review

THE VALUE OF ROUTINE PROCTOSCOPY FOR SURGEONS.

Total management of hemangiopericytoma/solitary fibrous tumor of the buttock: A case report

[Diagnosis and Surgical Treatment for Non-Functional Islet Cell Tumor: a Retrospective Analysis of 44 Cases].

Doege-Potter syndrome due to a solitary fibrous tumor of the pleura: a case report

Heterogeneity of Multiple Pancreatic Neuroendocrine Tumors Identified by 68Ga-DOTANOC and 68Ga-exendin-4 PET/CT in a Patient with Endogenous Hyperinsulinemic Hypoglycemia and Multiple Endocrine Neoplasia 1

Electroconvulsive Therapy Resurrected: Its Successes and Promises after 75 Years